Target Group Inc (CBDY) Fair Value & Analysis
Healthcare · US · Market cap $926K
Target Group Inc
CBDY · US
Fair value as of: Aug 13, 2026
From 5 valuation models · updated 4 days ago
Below-average quality, screening 33% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($0.0012). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.0008 – $0.0300 · the $0.0009 price screens below the $0.0012 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Target Group Inc (CBDY) currently trades at $0.0009, while our model-based Fair Value estimate is $0.0012, implying the stock looks roughly 33.3% undervalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Target Group Inc generated revenue of $3.4M at a net margin of -53.6%. Revenue declined 37.2% year over year. Fundamentals as of Aug 13, 2026
The share trades about 70% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 33%, CBDY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 5 models by family
Widest divergence: Multiples ($0.0012) versus Earnings-Based ($0.0002). Highest evidence: ROIC Compounder (67).
Notify me when CBDY reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 31 · Market factors (momentum, volatility) 7
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Target Group Inc. engages in the cultivation, processing, and distribution of curated cannabis products for the medical and adult-use recreational cannabis market in Canada and the United States.
Full company description
Target Group Inc. engages in the cultivation, processing, and distribution of curated cannabis products for the medical and adult-use recreational cannabis market in Canada and the United States. The company offers cannabis pre-rolls, and flower and extract pods for vaporizer use; K-Cup infused coffee and tea pods; and infused cannabis beverages, edibles, and topical products and CBD wellness products. It also provides a single-use pre-measured pod and vaporizer system for consumers interested in vaporizing natural herbs, including cannabis under The Wisp and Wisp Pods brands. The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018. Target Group Inc. was incorporated in 2013 and is based in Hamilton, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Target Group Inc reported revenue of $3.9M in FY2025 versus $0 in FY2021. Reported net income was −$1.4M in FY2025.
Watch CBDY: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Target Group Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Target Group Inc (CBDY) overvalued or undervalued?
What is the fair value of CBDY?
What is the quality score of CBDY?
What is the revenue of Target Group Inc (CBDY)?
What is the net profit margin of CBDY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Target Group Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.